Second-line avelumab is effective in patients with MSI-H/dMMR mCRC Presented ByProf. Julien Taieb, Hopital European George Pompidou, France TrialPhase 2, SAMCO-PRODIGE 54 ConferenceESMO 2022 16 November, 2022 17:13